Atezolizumab, also known as MPDL3280A, a high affinity-specific against PD-L1, is FDA approved for use in metastatic NSCLC after disease progression on platinum-containing chemotherapy. However, as it is a humanized antibody, it is immunogenic in mice. To overcome this issue, MPDL3280A-mIgG1-D265A was generated by recombinant DNA technology . Importantly, its constant region contains a point mutation D265A (a replacement of aspartic acid by alanine at position 265), resulting in the complete loss of cytolytic effector functions.
Specifications
Catalog Number:
KP-2027
Antibodies Name:
MPDL3280A-mIgG1-D265A
Host Cell Line:
EXPI-CHO
Target:
Mouse-PDL1
Species Reactivity:
Human
Application:
FACS | FACS Blocking | KD
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC/ FACS | FACS Blocking | KD
imageslabel1
imageslabel2
imageslabel3
imageslabel4
imageslabel5
imageslabe6
imageslabel7
Characterization
Application
References
1.Cortinovis D, von Pawel J, Syrigos K, et al. Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: safety population analyses from the Ph III study OAK. Ann Oncol 2017;28:v468ÿ96.
2.Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837ÿ46.
